Roche has a deal to sell an API plant in South Carolina to CDMO Patheon for a nominal amount, a deal that will save about 200 jobs at the plant in Florence which the Swiss drugmaker was preparing to close.
Durham, NC-based Patheon said it has a definitive agreement to buy the 1,100-acre, 300,000-square-foot facility for what it said is an “immaterial sum, plus the cost of associated inventory and spare parts.”
It also has a multiyear year deal to supply Roche with APIs that will help cover the costs of the facility until the contractor can get new business into it. Patheon said the facility will expand its capacity for manufacturing highly potent compounds, while adding micronization capabilities and commercial spray drying.
“The company will benefit from the additional North American API capacity and adds a state-of-the-art facility with approximately 200 scientific and manufacturing professionals,” Patheon CEO James Mullen said in a statement.
In an emailed statement, Roche spokeswomen Anja von Treskow said Tuesday the deal with Patheon, which is already a supplier to Roche, is expected to close within 60 days.
Roche said last year it would close the Florence plant, along with plants in Clarecastle, Ireland; Leganes, Spain, and Segrate, Italy, as part of a cost-saving plan that would remove about 1,200 jobs from its payroll. It took a charge of about $1.6 billion for the closures.
While its decision was firm, the Swiss drugmaker said it was trying to sell the plants to save jobs. In June, Greek contract manufacturer Famar said it had struck a deal to take the Leganes, Spain, plant and to supply Roche with APIs.
“In regards to the other sites, we can confirm that we are continuing with our efforts to divest Leganés and Segrate as operational sites to a reputable company, while Clarecastle is in the process of ramping down with production estimated to end in 2019. At this point in time we cannot comment further,” Roche said in its statement.
By Eric Palmer
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
